Hairy Cell Leukemia

Suspect HCL in a patient with otherwise unexplained cytopenias and splenomegaly, especially when peripheral blood or marrow shows lymphoid cells with irregular cytoplasmic projections. Bone marrow evaluation is central because classic HCL characteristically involves marrow and may produce peripheral cytopenias even when circulating hairy cells are sparse. BMJ+1BMJHairy cell leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticeOxford AcademicImmunohistochemistry for BRAF V600E in the Differential ...

Use integrated morphology, flow cytometry, immunohistochemistry, and molecular testing to distinguish classic HCL from HCL variant and other small B-cell neoplasms. BRAF V600E testing is particularly decision-relevant: the mutation occurs in almost all classic-form HCL and provides the biologic rationale for vemurafenib; BRAF V600E immunohistochemistry can assist in the differential diagnosis. Oxford Academic+1Oxford AcademicImmunohistochemistry for BRAF V600E in the Differential ...PubMedHairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

Do not extrapolate classic-HCL treatment response to HCL variant. HCL variant has poorer and less durable responses to standard purine analogs, so a diagnostic label of HCL variant should redirect management toward disease-specific specialist planning rather than routine cladribine or pentostatin monotherapy. ScienceDirect+1ScienceDirectHairy cell leukemia: Update on molecular profiling and ...ASHUpdated consensus guidelines for the diagnosis and ...

For stable patients without an indication for treatment, use close observation until treatment indications occur. This avoids exposing an indolent disease course to purine-analog-associated hematologic and immunologic toxicity before a treatment benefit is expected. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticeNEJMVemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia | New England Journal of Medicine

Escalate from observation when disease produces treatment-relevant cytopenias, symptomatic or massive splenomegaly, splenic rupture, or a platelet count low enough to preclude chemotherapy. Massive symptomatic splenomegaly or splenic rupture changes the immediate management pathway because splenic-directed intervention may be required when chemotherapy cannot be safely delivered. BMJBMJHairy cell leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice

Before initiating cladribine or pentostatin, perform pretreatment evaluation focused on infection and establish infection control. Active infection is a key reason to defer a purine analog and select a less myelosuppressive bridge or alternative regimen. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticePubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMed

For classic HCL requiring treatment and without a contraindicating infection or major fitness limitation, use cladribine or pentostatin as standard first-line therapy. Historical first-line complete remission rates with purine analogs are approximately 75% to 90%, although relapse can occur years later and repeated exposure accumulates hematologic and immunologic toxicity. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticeScienceDirectPhase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia - ScienceDirect

Adding rituximab concurrently to cladribine improves the MRD-free complete-response rate compared with delayed rituximab in first-line HCL. This depth-of-response advantage should be weighed against the added immune effects of anti-CD20 therapy, particularly in a patient whose infection history or current infectious status already argues for minimizing immunosuppression. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticePubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMed

When a purine analog is unsuitable because of active infection, frailty, or renal insufficiency, vemurafenib is an alternative that can be used alone or with rituximab or obinutuzumab. Vemurafenib-based initial treatment has demonstrated rapid blood-count recovery, making it particularly useful when count restoration is needed but purine-analog myelosuppression is undesirable. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticeNEJMVemurafenib and Obinutuzumab as Frontline Therapy for ...

If pentostatin produces a complete response, two or three additional pentostatin doses may be considered. Document response using standardized response assessment because response, relapse, and MRD definitions remain important for comparing treatment programs; MRD testing has not been validated as a clinically significant endpoint for routine decision-making. BMJ+2BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticePubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMedPubMedHairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

At relapse, first distinguish late relapse from early relapse or refractory disease. Patients relapsing after a first purine-analog course often respond to retreatment with the same or another purine analog, particularly when relapse occurs after 2 years; this is the principal setting in which another purine-analog course remains reasonable. BMJ+1BMJHairy cell leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticePubMedHairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

Avoid serially repeating purine analogs without considering cumulative toxicity and diminishing benefit. Relapsed HCL can become progressively less sensitive to purine analogs, and repeated courses produce cumulative hematologic and immunologic toxicity. Cross-resistance between cladribine and pentostatin can occur. NEJM+1NEJMVemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia | New England Journal of MedicineScienceDirectPhase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia - ScienceDirect

For BRAF V600E-positive relapsed or refractory classic HCL, vemurafenib with rituximab offers a chemotherapy-free strategy. In a prospective study of heavily pretreated patients, this combination achieved complete response in 87%, MRD-negative status in 60%, and relapse-free survival of 85% at a median follow-up of 34 months. NEJMNEJMVemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia | New England Journal of Medicine

Rituximab alone can induce durable complete remissions with minimal toxic effects in multiply relapsing or refractory HCL after prior purine analog therapy, while combinations or sequential rituximab with cladribine or pentostatin are effective for complete-remission induction. Choose between these approaches according to prior purine-analog sensitivity, cumulative immunosuppression, and the need for a chemotherapy-free regimen. PubMedPubMedHairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

For multiply relapsed disease, enroll in a clinical trial whenever feasible. This is particularly important after loss of durable benefit from purine analogs or BRAF-directed therapy and in HCL variant, where standard classic-HCL treatment assumptions are unreliable. PubMed+1PubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMedASHUpdated consensus guidelines for the diagnosis and ...

Track blood counts and clinical spleen-related symptoms during treatment and follow-up, because cytopenia recovery and resolution of disease-related manifestations are the immediate measurable objectives of therapy. Vemurafenib-based therapy has been associated with rapid count recovery in initial treatment, whereas purine analogs require particular attention to hematologic and immunologic toxicity. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticeNEJMVemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia | New England Journal of Medicine

Maintain a low threshold to evaluate fever or focal infectious symptoms before, during, and after treatment because HCL is associated with marked susceptibility to infection and effective therapies can deepen immunosuppression. Before any subsequent purine-analog course, repeat pretreatment evaluation and infection-control planning rather than assuming a prior uncomplicated course predicts safety. BMJ+1BMJHairy cell leukaemia - Treatment algorithm | BMJ Best PracticePubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMed

Use clinical status, blood counts, and standardized response assessment to determine relapse requiring intervention. MRD testing may characterize depth of response, but its clinical significance as a routine endpoint has not been validated; do not treat MRD positivity alone as established evidence of a need for salvage therapy. PubMed+1PubMedConsensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia - PubMedPubMedHairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf